Clinical Trial: Semaglutide Versus Placebo in <scp>NIT</scp> ‐Assessed <scp>MASH</scp> —A Multicenter Randomised Placebo‐Controlled Trial ( <scp>SAMARA</scp> )
A NIT-based approach to identify at-risk MASH patients for semaglutide treatment is feasible and effective. This study provides RCT data showing that FAST, ALT, AST and MRI-PDFF can be used to monitor treatment response.
Authors
- Vuppalanchi Raj
- Eduardo Grunvald (ORCID: https://orcid.org/0000-0001-9332-7069)
- Harris Siddiqi (ORCID: https://orcid.org/0000-0001-7434-9158)
- Tincopa MA
- Ottar Lunde (ORCID: https://orcid.org/0000-0003-2357-1271)
- Ruth Abeles
- Seema Singh
- Ricki Bettencourt
- Feng He
- Lisa Richards
- Darryl Contrano
- Mandana Khalili
- Muhammad Y. Sheikh
- Heather Hofflich
- Diana Cortez‐Moreno
- Joseph Risser
- Sonia Jain
- Rohit Loomba
- Samuel Klein
Institutions
- University of San Diego (US)
- University of California, San Francisco (US)
- Washington University in St. Louis (US)
- Fresno City College (US)
- University of California San Diego (US)
- Advanced Targeting Systems (United States) (US)
- Indiana University Bloomington (US)
- Human Longevity (United States) (US)
- General Atomics (United States) (US)
- California State University, Fresno (US)
Publication Details
- Journal
- Alimentary Pharmacology & Therapeutics
- Published
- 2026-01-12
- DOI
- https://doi.org/10.1111/apt.70516
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 92.19
Funders
- Novo Nordisk
- National Heart, Lung, and Blood Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Advancing Translational Sciences